Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024
May 13, 2024 09:00 ET
|
Chromocell Corporation
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
Chromocell Issues Letter to Stockholders from Chief Executive Officer
April 09, 2024 08:30 ET
|
Chromocell Corporation
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
March 21, 2024 08:30 ET
|
Chromocell Corporation
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
March 18, 2024 10:00 ET
|
Chromocell Corporation
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
March 11, 2024 09:00 ET
|
Chromocell Corporation
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
February 27, 2024 08:00 ET
|
Chromocell Corporation
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO),...
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
February 21, 2024 16:47 ET
|
Chromocell Corporation
FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on...
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
February 16, 2024 08:00 ET
|
Chromocell Corporation
FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing...